RANI Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Stats
Today's Volume	187 808
Average Volume	128 288
Market Cap	330.72M
EPS	$0 ( 2024-03-27 )
Next earnings date	( $-0.230 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.93
ATR14	$0.0240 (0.37%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-21	Mckinley Kate	Buy	323 500	Stock Option (Right to Buy)
2024-03-21	Hashim Mir	Buy	323 500	Stock Option (Right to Buy)
2024-03-21	Groen Eric	Buy	323 500	Stock Option (Right to Buy)
2024-03-21	Imran Talat	Buy	1 085 000	Stock Option (Right to Buy)
2024-03-21	Sanford Svai S	Buy	323 500	Stock Option (Right to Buy)

INSIDER POWER
19.25
Last 99 transactions
Buy: 12 150 348 \| Sell: 8 157 844

Volume Correlation

Long: 0.19 (neutral)

Short: 0.29 (neutral)

Signal:(66.392) Neutral

Rani Therapeutics Correlation

10 Most Positive Correlations
LWAY	0.823

10 Most Negative Correlations
FAT	-0.836
APPF	-0.832
FSTR	-0.826
DATS	-0.825
ENTG	-0.825
ALGT	-0.818

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Rani Therapeutics Correlation - Currency/Commodity

-0.15
( neutral )

0.13
( neutral )

0.00
( neutral )

-0.40
( neutral )

-0.24
( neutral )

0.52
( weak )

Rani Therapeutics Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-822 000 (0.00 %)
EPS:	$-1.330

Q4	2023
Revenue:	$0
Gross Profit:	$-227 000 (0.00 %)
EPS:	$-0.270

Q3	2023
Revenue:	$0
Gross Profit:	$-478 000 (0.00 %)
EPS:	$-0.360

Q2	2023
Revenue:	$0
Gross Profit:	$-449 000 (0.00 %)
EPS:	$-0.370

Financial Reports:

No articles found.

Rani Therapeutics

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.